Evrenzo

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Roxadustat

Available from:

Astellas Pharma Europe B.V.

ATC code:

B03XA05

INN (International Name):

roxadustat

Therapeutic group:

Preparazzjonijiet antianemiċi

Therapeutic area:

Anemia; Kidney Failure, Chronic

Therapeutic indications:

Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).

Product summary:

Revision: 3

Authorization status:

Awtorizzat

Authorization date:

2021-08-18

Patient Information leaflet

                                46
B. FULJETT TA’ TAGĦRIF
47
FULJETT TA’ TAGĦRIF: INFORMAZZJONI IMPORTANTI GĦALL-PAZJENT
Evrenzo 20
mg pilloli miksija b’rita
Evrenzo 50
mg pilloli miksija b’rita
Evrenzo 70
mg pilloli miksija b’rita
Evrenzo 100
mg pilloli miksija b’rita
Evrenzo 150
mg pilloli miksija b’rita
roxadustat
Dan il-
prodott mediċinali huwa suġġett għal monitoraġġ addizzjonali.
Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar is
-
sigurtà. Inti tista’ tgħin billi tirrapporta
kwalunkwe effett sekondarju li jista’ jkollok. Ara t
-
tmiem ta’ sez
zjoni
4 dwar kif għandek tirrapporta
effetti sekondarji.
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il
-
fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-
ispiżjar tiegħek.
-
Din il-
mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha lil
persuni oħra. Tista’
tagħmlilhom il
-
ħsara anke jekk għandhom l­istess sinjali ta’ mard bħal
tiegħek.
-
Jekk ikollok xi effett sekondarju, kellem lit-tabib jew lill-
ispiżjar tiegħek.
Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il
-fuljett. Ara sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Evrenzo u għalxiex jintuża
2.
X'għandek tkun taf qabel ma tieħu Evrenzo
3.
Kif
għandek tieħu Evrenzo
4.
Effetti sekondarji possibbli
5.
Kif taħżen Evrenzo
6.
Kontenut tal-
pakkett u informazzjoni oħra
1.
X’INHU EVRENZO U GĦALXIEX JINTUŻA
X’INHU EVRENZO
Evrenzo huwa mediċina li żżid in
-
numru ta’ ċelloli ħomor tad
-demm u l-
livell ta’
emoglobina fid-
demm tiegħek. Fih is
-sustanza attiva roxadustat.
GĦALXIEX JINTUŻA EVRENZO
Evrenzo jintuża biex jittratta adulti b’anemija
sintomatika
li sseħħ f’pazjenti b’mard kroniku tal
-
kliewi. L-
anemija hija meta jkollok wisq ftit ċelloli ħomor tad
-demm u l-livell tal-
emoglobina tiegħek
ikun baxx wisq. B’hekk, ġismek jista’ ma jirċevix 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
Dan il-
prodott mediċinali huwa suġġett għal monitoraġġ addizzjonali.
Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar is
-sigurtà. Il-professjonisti tal-kura tas-
saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
Evrenzo
20
mg pilloli miksija b’rita
Evrenzo
50
mg pilloli miksija b’rita
Evrenzo
70
mg pilloli miksija b’rita
Evrenzo
100
mg pilloli miksija b’rita
Evrenzo
150
mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Evrenzo 20 mg pilloli mik
sija b’rita
Kull pillola fiha 20 mg roxadustat.
Evrenzo 50
mg pilloli miksija b’rita
Kull pillola fiha 50 mg roxadustat.
Evrenzo 70
mg pilloli miksija b’rita
Kull pillola fiha 70 mg roxadustat.
Evrenzo 100
mg pilloli miksija b’rita
Kull pillola fiha 100 mg roxadustat.
Evrenzo 150
mg pilloli miksija b’rita
Kull pillola fiha 150 mg roxadustat.
Eċċipjent(i) b’effett magħruf
Kull pillola ta’
20
mg miksija b’rita fiha 40.5
mg lactose, 0.9 mg Allura Red AC aluminium lake u
0.21
mg leċitina tas
-sojja.
Kull
pillola ta’
50
mg miksija b’rita fiha 101.2
mg lactose, 1.7 mg Allura Red AC aluminium lake u
0.39
mg leċitina tas
-sojja.
Kull pillola ta’
70
mg miksija b’rita fiha 141.6
mg lactose, 2.1 mg Allura Red AC aluminium lake u
0.47
mg leċitina tas
-sojja.
Kull p
illola ta’
100
mg miksija b’rita fiha 202.4
mg lactose, 2.8 mg Allura Red AC aluminium lake u
0.63
mg leċitina tas
-sojja.
Kull pillola ta’
150
mg miksija b’rita fiha 303.5
mg lactose, 3.7 mg Allura Red AC aluminium lake u
0.84
mg leċitina tas
-sojja.
Għal
-
lista sħiħa ta’ eċċipjenti, ara sezzjoni
6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pilloli miksija b’rita (pilloli).
Evrenzo
pilloli ta’ 20
mg
Pilloli ħomor, ovali (madwar
8 mm× 4
mm) b’“20” imnaqqxa fuq naħa waħda.
Evrenzo
pilloli ta’ 50
mg
Pilloli ħomor, ovali
(madwar 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 08-06-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 08-06-2023
Public Assessment Report Public Assessment Report Bulgarian 07-12-2021
Patient Information leaflet Patient Information leaflet Spanish 08-06-2023
Public Assessment Report Public Assessment Report Spanish 07-12-2021
Patient Information leaflet Patient Information leaflet Czech 08-06-2023
Public Assessment Report Public Assessment Report Czech 07-12-2021
Patient Information leaflet Patient Information leaflet Danish 08-06-2023
Public Assessment Report Public Assessment Report Danish 07-12-2021
Patient Information leaflet Patient Information leaflet German 08-06-2023
Public Assessment Report Public Assessment Report German 07-12-2021
Patient Information leaflet Patient Information leaflet Estonian 08-06-2023
Public Assessment Report Public Assessment Report Estonian 07-12-2021
Patient Information leaflet Patient Information leaflet Greek 08-06-2023
Public Assessment Report Public Assessment Report Greek 07-12-2021
Patient Information leaflet Patient Information leaflet English 08-06-2023
Public Assessment Report Public Assessment Report English 24-08-2021
Patient Information leaflet Patient Information leaflet French 08-06-2023
Public Assessment Report Public Assessment Report French 07-12-2021
Patient Information leaflet Patient Information leaflet Italian 08-06-2023
Public Assessment Report Public Assessment Report Italian 07-12-2021
Patient Information leaflet Patient Information leaflet Latvian 08-06-2023
Public Assessment Report Public Assessment Report Latvian 07-12-2021
Patient Information leaflet Patient Information leaflet Lithuanian 08-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-06-2023
Public Assessment Report Public Assessment Report Lithuanian 07-12-2021
Patient Information leaflet Patient Information leaflet Hungarian 08-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 08-06-2023
Public Assessment Report Public Assessment Report Hungarian 07-12-2021
Patient Information leaflet Patient Information leaflet Dutch 08-06-2023
Public Assessment Report Public Assessment Report Dutch 07-12-2021
Patient Information leaflet Patient Information leaflet Polish 08-06-2023
Public Assessment Report Public Assessment Report Polish 07-12-2021
Patient Information leaflet Patient Information leaflet Portuguese 08-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 08-06-2023
Public Assessment Report Public Assessment Report Portuguese 07-12-2021
Patient Information leaflet Patient Information leaflet Romanian 08-06-2023
Public Assessment Report Public Assessment Report Romanian 07-12-2021
Patient Information leaflet Patient Information leaflet Slovak 08-06-2023
Public Assessment Report Public Assessment Report Slovak 07-12-2021
Patient Information leaflet Patient Information leaflet Slovenian 08-06-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 08-06-2023
Public Assessment Report Public Assessment Report Slovenian 07-12-2021
Patient Information leaflet Patient Information leaflet Finnish 08-06-2023
Public Assessment Report Public Assessment Report Finnish 07-12-2021
Patient Information leaflet Patient Information leaflet Swedish 08-06-2023
Public Assessment Report Public Assessment Report Swedish 07-12-2021
Patient Information leaflet Patient Information leaflet Norwegian 08-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 08-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 08-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 08-06-2023
Patient Information leaflet Patient Information leaflet Croatian 08-06-2023
Public Assessment Report Public Assessment Report Croatian 07-12-2021

Search alerts related to this product

View documents history